3,881
edits
Changes
Gene-Specific Template (Updated 9-28-21) (view source)
Revision as of 13:56, 28 September 2021
, 13:56, 28 September 2021no edit summary
EXAMPLE:
EXAMPLE:
* ''TP53'' is a well-described tumor suppressor gene that functions in apoptosis, genomic stability and inhibition of angiogenesis (RefSeq, Dec 2016).
*''TP53'' is a well-described tumor suppressor gene that functions in apoptosis, genomic stability and inhibition of angiogenesis (RefSeq, Dec 2016).
* Germline loss-of-function alterations, including deletions, are associated with Li-Fraumeni cancer predisposition syndrome (LFS). Individuals with LFS are at an increased risk of developing cancer, particularly sarcomas (PMID: 20586629, 27621308, 25896519).
*Germline loss-of-function alterations, including deletions, are associated with Li-Fraumeni cancer predisposition syndrome (LFS). Individuals with LFS are at an increased risk of developing cancer, particularly sarcomas (PMID: 20586629, 27621308, 25896519).
* Somatic ''TP53'' alterations are reported at a high frequency across a wide range of tumors, arising in ~30% of all cancer patients (PMID: 25400752, 27239089, cbioportal.org accessed 6/2/21).
*Somatic ''TP53'' alterations are reported at a high frequency across a wide range of tumors, arising in ~30% of all cancer patients (PMID: 25400752, 27239089, cbioportal.org accessed 6/2/21).
==Clinical Cancer Associations (Somatic)==
==Clinical Cancer Associations (Somatic)==
(''Instruction: include references and links to related internal CCGA pages'')
{| class="wikitable"
{| class="wikitable"
|'''Tumor Type'''
|'''Tumor Type'''
|'''Therapeutic Significance (Yes, No or Unknown)'''
|'''Therapeutic Significance (Yes, No or Unknown)'''
|-
|-
|EXAMPLE: Chronic Myeloid Leukemia (CML), BCR-ABL1 Positive (link to internal page through this name)
|EXAMPLE: Chronic Myeloid Leukemia (CML), BCR-ABL1 Positive (link this name to internal page using link icon above)
|EXAMPLES: Copy Number Loss, Copy Number Gain, LOH, Loss-of-Function Mutation, Gain-of-Function Mutation, Translocation/Fusion, Expression Changes (Biomarker), Somatic Hypermutation
|EXAMPLES: Copy Number Loss, Copy Number Gain, LOH, Loss-of-Function Mutation, Gain-of-Function Mutation, Translocation/Fusion, Expression Changes (Biomarker), Somatic Hypermutation
|
|
==Clinical Cancer Associations (Germline)==
==Clinical Cancer Associations (Germline)==
(''Instruction: include references and links to related internal CCGA pages'')
{| class="wikitable"
{| class="wikitable"
|'''Tumor Type'''
|'''Tumor Type'''
|'''Therapeutic Significance (Yes, No or Unknown)'''
|'''Therapeutic Significance (Yes, No or Unknown)'''
|-
|-
|EXAMPLE: Myeloid Neoplasms with Germline ANKRD26 Mutation (link to internal page through this name)
|EXAMPLE: Myeloid Neoplasms with Germline ANKRD26 Mutation (link this name to internal page using link icon above)
|EXAMPLES: Copy Number Loss, Copy Number Gain, LOH, Loss-of-Function Mutation, Gain-of-Function Mutation, Translocation/Fusion,
|EXAMPLES: Copy Number Loss, Copy Number Gain, LOH, Loss-of-Function Mutation, Gain-of-Function Mutation, Translocation/Fusion,
|
|
|
|
|-
|-
|}
|}